Iron Deficiency Anemia | Market Size, Share & Growth Report 2025-2033

North America is the largest market here on documented commercial concentration rather than on a measured regional market size. The concentration is in price and indication rather than in patients. The FDA approved Injectafer in June 2023 for iron deficiency in adults with heart failure of New York Heart Association class II or III. It was the first intravenous iron therapy in the United States to carry that indication, and the approval was granted to American Regent, a Daiichi Sankyo Group company. Intravenous iron is priced far above oral therapy and is administered in supervised settings that support that pricing. No regional market size, revenue or growth figure was identified for any region in this market, and no company examined reports iron therapy revenue by region, so both regional rankings here are documented judgements rather than measurements.

Europe is where much of the intravenous iron development originated, with CSL Vifor marketing ferric carboxymaltose as Ferinject outside North America and Pharmacosmos supplying ferric derisomaltose from Denmark. The region's clinical practice has been comparatively willing to use intravenous iron, particularly in perioperative patient blood management programmes where correcting anaemia before surgery reduces transfusion. National tendering holds prices below United States levels, so Europe's share of patients exceeds its share of value. Shield Therapeutics developed its oral ferric maltol product here before taking it to the United States. No European market size, revenue or growth figure was identified.

Asia Pacific is named the fastest-growing region here on documented disease burden and treatment expansion rather than on measured market growth, and that basis should be read as a judgement rather than a measurement. Iron deficiency anaemia is far more prevalent across South and Southeast Asia than in high-income regions, particularly among women of reproductive age and young children, so the untreated population is very large. The commercial consequence is asymmetric: the number of people needing treatment is enormous while the revenue per patient is small, because oral ferrous salts rather than intravenous molecules do most of the work. No regional market size, revenue or growth figure was identified for this or any other region in this market, so the ranking is a documented judgement rather than a measured one. Growth depends on intravenous therapy reaching hospital formularies rather than on more patients being identified.

No market size, revenue or access figure specific to Latin America was identified for this market. Iron deficiency anaemia is a recognised public health priority across the region, addressed substantially through food fortification programmes and antenatal supplementation rather than through pharmaceutical purchasing. Public tendering dominates what drug procurement there is, which favours oral ferrous salts over intravenous molecules. Intravenous iron use is concentrated in private hospitals and larger public centres, typically for patients who have failed oral therapy or need correction before surgery.

No market size, revenue or access figure specific to the Middle East and Africa was identified for this market. The region carries a substantial share of global iron deficiency anaemia, and in much of Africa the response runs through supplementation and fortification programmes funded by health ministries and donors rather than through commercial pharmaceutical sales. Gulf states purchase current intravenous molecules for hospital use and operate the infusion capacity those products require. The gap between the size of the affected population and the value of the market is wider here than in any other region.